The month ahead: April’s upcoming events
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Orca heads to the FDA
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
